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Abstract: Despite the well-understood importance of beta-blocker therapy in heart failure, it 
is sometimes not possible to use beta-blockers in elderly patients due to poor tolerance. In this 
report, we describe the case of an 83-year-old patient with severe systolic heart failure compli-
cated by aortic valve stenosis and atrial fibrillation. A simple therapeutic approach involving 
discontinuation of beta-blockers remarkably alleviated the symptoms such as left ventricular 
ejection fraction, and improved the chest radiography and laboratory findings; further, atrial 
fibrillation converted to sinus rhythm. It is important to carefully administer beta-blocker therapy 
to elderly patients with heart failure, especially after considering cardiac output.
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Introduction
It is well established that beta-blocker therapy reduces morbidity and mortality in heart 
failure patients.1,2 With advances in the management of heart disease and the widespread 
recognition of their effects, beta-blockers are the mainstay of the current treatment for 
heart failure. However, they can cause adverse effects such as hypotension, bradycardia, 
and reversible pulmonary disease. Because some patients have poor tolerance towards 
beta-blockers, dosage reduction or discontinuation is sometimes necessary, despite 
the advantages of beta-blockers. In this report, we describe the case of a patient with 
severe heart failure complicated by aortic valve stenosis and atrial fibrillation, which 
were dramatically improved after discontinuation of beta-blockers.
Case report
An 83-year-old woman with a history of heart failure and repeated hospitalization 
due to decompensated heart failure (New York Heart Association [NYHA] functional 
classification class III) was transferred to our institution on the recommendation of 
a nearby general practitioner one year ago. The patient had acute heart failure, and 
severe complications were recorded after conducting several intensive examinations. 
The electrocardiogram (ECG) obtained at admission revealed atrial fibrillation with 
a QS pattern in the V1–V3 leads, indicating an old myocardial infarction. Her mean 
heart rate was 60−70 beats/min. Two-dimensional transthoracic echocardiography 
revealed a slightly dilated left atrium and ventricle, and severe hypokinesis in the 
left ventricle from the septal to the apical area. The left ventricular ejection fraction 
(LVEF) was 25%. A severe degree of aortic valve stenosis with calcification was 
observed (peak velocity, 2.9 m/s; peak transvalvular gradient, 33 mmHg; and indexed Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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valve area, 0.55 cm2, indicating reduced blood flow and 
  low-gradient aortic   stenosis). Further, a severe degree of 
tricuspid regurgitation was observed. On the basis of the ECG 
and echocardiographic findings, we elected to perform cath-
eter angiography that revealed severe coronary artery stenosis 
in the left anterior descending artery and severe peripheral 
artery disease (total occlusion of the left iliac artery and 
severe stenosis in the superficial femoral artery). Despite the 
advanced age of the patient and the presence of comorbidities, 
we recommended invasive treatment with percutaneous coro-
nary intervention or aortic valve replacement on the basis of 
catheterization and echocardiographic findings; however, the 
patient and her family refused the invasive treatment, and she 
was administered optimal medical therapy. The patient was 
already taking aspirin, angiotensin-receptor blockers, statin, 
diuretic agents, and beta-blocker bisoprolol (2.5 mg/day) for 
coronary artery disease, heart failure, and atrial fibrillation. 
These medications were continued after discharge.
After discharge from the first hospitalization, her 
condition gradually worsened. She was hospitalized many 
times due to heart failure, and diuretic agent dose was 
gradually increased. The dose of N-terminal pro-brain 
natriuretic peptide (NT-proBNP) was markedly elevated 
to 8739 pg/mL, suggesting severe heart failure that was 
difficult to control. A chest radiograph showed cardio-
megaly with a cardiothoracic ratio of 71% (Figure 1A). 
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Figure 2 Clinical course and treatment of the patient, and the change in N-terminal 
pro-brain  natriuretic  peptide  (NT-proBNP).  After  bisoprolol  discontinuation, 
NT-proBNP gradually decreased. Approximately 2 months later, atrial fibrillation 
had spontaneously converted to sinus rhythm.
Figure 1 At the time of the most severe condition, the chest radiograph showed 
cardiomegaly  with  cardiothoracic  ratio  (CTR)  of  71%;  an  electrocardiogram 
revealed atrial fibrillation with a QS pattern in the V1–V3 leads A). After bisoprolol 
discontinuation, the CTR determined by chest radiography was reduced to 57%, and 
atrial fibrillation converted to sinus rhythm B).
She was confined to a wheelchair with care support and 
could not walk by herself because of dyspnea, chest pain, 
and lack of physical   activity. We carefully re-evaluated 
her condition, and observed a decreased heart rate of less 
than 60 beats/min. Bisoprolol was discontinued on sus-
picion that it caused bradycardia, which indicated very 
poor heart function.
After bisoprolol discontinuation, the condition of the 
patient gradually improved. Dyspnea and effort angina 
disappeared, and she could walk by herself without care 
support. Her functional capacity improved to NYHA class II. 
Two months after bisoprolol discontinuation, transthoracic 
echocardiography revealed a significant improvement of 
62% in the LVEF and a marked reduction in the tricuspid 
regurgitation degree. The cardiothoracic ratio, determined 
by chest radiography, was reduced to 57% (Figure 1B). The 
NT-proBNP level was 2962 pg/mL. Finally, atrial fibril-
lation was spontaneously terminated, and sinus rhythm 
was maintained; the mean heart rate was approximately 
50–60 beats/min. The total clinical course and treatment of 
the patient are summarized in Figure 2.
Discussion
We report a case of a patient with heart failure who showed 
remarkable improvement following discontinuation of beta-
blocker therapy. Not only did heart failure symptoms and 
quality of life improve but also objective results such as ECG, 
chest radiography, laboratory test, and echocardiography 
findings clearly improved.
There is a great deal of evidence of the clinical efficacy 
of beta-blockers in the young general population; however, 
few studies have investigated its efficacy in elderly patients Clinical Interventions in Aging 2010:5 submit your manuscript | www.dovepress.com
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and most trials exclude very elderly patients, the prevalence 
of bradyarrythmia due to beta-blockers may be higher than 
expected in these patients.11
In the present case, although bisoprolol was adminis-
tered in very small doses and the change in heart rate was 
relatively small (approximately 10 beats/min), the benefit of 
bisoprolol discontinuation was beyond our expectation. We 
speculate that beta-blockers not only decreased heart rate 
but also excessively restricted left ventricular contraction 
and markedly decreased cardiac output. Aging is associated 
with a reduction in the intrinsic heart rate and cardiac output 
but are generally maintained by increasing stroke volume.12 
Because heart rate response to exercise effort is reduced in 
elderly patients, stroke volume plays an important role in 
conducting cardiac output. In the present case, severe aortic 
valve stenosis further restricted cardiac output, resulting 
in lowered systolic cardiac output and decreased LVEF. 
Bisoprolol discontinuation may contribute to softening of 
the restricted left ventricular contraction and improvement 
of the decreased cardiac output. The reason for the restora-
tion of the sinus rhythm was that improved cardiac output 
decreased volume overload and reduced burden on the 
heart to terminate atrial fibrillation that had persisted for a 
long period.
Our approach of treatment for this patient was only the 
discontinuation of beta-blockers. Although this approach 
is very simple, it is very important that beta-blockers are 
administered to elderly patients with caution. The reduced 
benefit of beta-blockers in elderly patients compared to 
younger patients can be explained by several factors such 
as age-induced decrease of response to beta-blockers, high 
prevalence of comorbidities including atrial fibrillation, 
and high risk of multiple-cause death.4,12 Moreover, slow 
metabolic processes and declined multiple organ systems 
could unexpectedly affect drug action response and the 
incidence of adverse reaction in the elderly. Additionally, 
some patients may not respond to beta-blockers or these 
drugs may induce adverse effects, especially in patients 
with systolic heart failure, depending on cardiac output, 
as was noted in the present case. Further clinical trials are 
necessary to assess the appropriate and sufficient condi-
tions in which elderly patients can benefit from receiving 
beta-blocker therapy, and to establish protocols for beta-
blocker removal.
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with heart failure. The SENIORS trial is the only trial that 
has evaluated the effects of the beta-blocker nebivolol in 
elderly heart failure patients aged more than 70 years (mean 
age, 76 years).3 The study showed that nebivolol signifi-
cantly reduced the risk of death or hospitalization. However, 
the overall risk reduction for the primary endpoint appeared 
to be less effective than that reported by other studies on 
younger patients. Another study showed that in patients with 
advanced chronic heart failure the relative risk reduction of 
all-cause death was significantly lower in older patients than 
in younger patients.4 In their study (mean age, 76 years), the 
risk reduction by use of beta-blockers decreases with age 
from 71% in patients aged 75 years to 21% in patients 
aged . 75 years. Although the effects of beta-blockers on 
mortality may be smaller in older patients than younger 
patients, these agents are still effective in improving 
mortality and hospitalization rates in elderly patients with 
heart failure.
In addition, sub-optimal doses of beta-blockers are 
often used in elderly patients with chronic heart failure. 
Numerous studies have shown that evidence-based heart 
failure therapies are underused, especially in the elderly 
patients.5,6 However, there are no large randomized trials 
that studied the relationship between dose-response and 
mortality in patients with heart failure. MOCHA, a relatively 
small study, was designed to evaluate dose-related effects of 
carvedilol in patients with moderate heart failure and found 
a dose-related improvement in mortality and LVEF.7 On 
the other hand, subgroup analyses from large trials did not 
show dose-relative effects on survival, but even low doses 
conferred benefit in their studies compared to placebo.8,9 
Thus, even if low doses of beta-blocker can be tolerated 
by elderly patients, their prescription is encouraged, and 
therapy is continued.
Our patient was receiving beta-blockers because of 
complication of coronary heart disease and heart failure 
due to low LVEF, which was expected to prevent severe 
outcomes. However, bradycardia, an adverse effect of 
beta-blockers, was considered to worsen the condition 
of heart failure. Bradycardia is one of the main causes of 
beta-broker treatment withdrawal. Even in patients without 
manifesting sinus or AV nodal conduction disease, beta-
blockers may result in adverse bradyarrhythmia events. In 
the MIAMI trial, although patients were pre-excluded if their 
heart rates were less than 65 beats/min, 12.9% of patients 
treated with metoprolol experienced adverse reactions due 
to bradycardia development.10 Because conduction system 
disease incidence is expected to be higher in older patients Clinical Interventions in Aging
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